These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38740705)

  • 1. Effects of incremental peritoneal dialysis with low glucose-degradation product neutral pH solution on clinical outcomes.
    Yeter HH; Altunok M; Cankaya E; Yildirim S; Akturk S; Bakirdogen S; Akoğlu H; Bulut M; Sahutoglu T; Erdut A; Ozkahya M; Koc Y; Tunca O; Kara E; Erek M; Polat M; Akagun T; Guz G
    Int Urol Nephrol; 2024 Sep; 56(9):3123-3132. PubMed ID: 38740705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental peritoneal dialysis: Is it better for preservation of residual kidney function and clinical outcomes?
    Fernandes A; Matias P; Branco P
    Clin Nephrol; 2023 Jan; 99(1):11-17. PubMed ID: 36472405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Incremental peritoneal dialysis with residual kidney function decline in patients on peritoneal dialysis: The balANZ trial.
    Hayat A; Cho Y; Hawley CM; Htay H; Krishnasamy R; Pascoe E; Teitelbaum I; Varnfield M; Johnson DW
    Perit Dial Int; 2023 Sep; 43(5):374-382. PubMed ID: 37259236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
    Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
    Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
    Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
    Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
    Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental dialysis in ESRD: systematic review and meta-analysis.
    Garofalo C; Borrelli S; De Stefano T; Provenzano M; Andreucci M; Cabiddu G; La Milia V; Vizzardi V; Sandrini M; Cancarini G; Cupisti A; Bellizzi V; Russo R; Chiodini P; Minutolo R; Conte G; De Nicola L
    J Nephrol; 2019 Oct; 32(5):823-836. PubMed ID: 30604150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volume-Based Peritoneal Dialysis Prescription Guide to Achieve Adequacy Targets.
    Akonur A; Firanek CA; Gellens ME; Hutchcraft AM; Kathuria P; Sloand JA
    Perit Dial Int; 2016; 36(2):188-95. PubMed ID: 26293841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical outcome between incremental peritoneal dialysis and conventional peritoneal dialysis: a propensity score matching study.
    Lee SM; Min YS; Son YK; Kim SE; An WS
    Ren Fail; 2021 Dec; 43(1):1222-1228. PubMed ID: 34396922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.
    Howard K; Hayes A; Cho Y; Cass A; Clarke M; Johnson DW
    Am J Kidney Dis; 2015 May; 65(5):773-9. PubMed ID: 25746151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compared decline of residual kidney function in patients treated with automated peritoneal dialysis and continuous ambulatory peritoneal dialysis: a multicenter study.
    Pérez Fontán M; Remón Rodríguez C; Borràs Sans M; Sánchez Álvarez E; da Cunha Naveira M; Quirós Ganga P; López-Calviño B; Rodríguez Suárez C; Rodriguez-Carmona A
    Nephron Clin Pract; 2014; 128(3-4):352-60. PubMed ID: 25572110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis.
    Wang J; Zhu N; Yuan W
    Nephron; 2015; 129(3):155-63. PubMed ID: 25765060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patients.
    Cho KH; Do JY; Park JW; Yoon KW; Kim YL
    Perit Dial Int; 2013; 33(4):382-90. PubMed ID: 23284074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
    Johnson DW; Clarke M; Wilson V; Woods F; Brown FG
    BMC Nephrol; 2010 Sep; 11():25. PubMed ID: 20843375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiologic and demographic aspects of peritoneal dialysis in Mexico.
    Su-Hernández L; Abascal-Macías A; Méndez-Bueno FJ; Paniagua R; Amato D
    Perit Dial Int; 1996; 16(4):362-5. PubMed ID: 8863327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental peritoneal dialysis: Clinical outcomes and residual kidney function preservation.
    Borràs Sans M; Chacón Camacho A; Cerdá Vilaplana C; Usón Nuño A; Fernández E
    Nefrologia; 2016; 36(3):299-303. PubMed ID: 27137104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
    Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
    Nephrol Dial Transplant; 2012 Dec; 27(12):4445-53. PubMed ID: 22859794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes of incremental vs. standard peritoneal dialysis: a systematic review and meta-analysis.
    Xu S; Wu W; Cheng J
    BMC Nephrol; 2024 Sep; 25(1):308. PubMed ID: 39285336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The balANZ Trial.
    Nataatmadja M; Cho Y; Pascoe EM; Darssan D; Hawley CM; Johnson DW;
    Perit Dial Int; 2017; 37(4):407-413. PubMed ID: 28408714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.